Generating Synthetic Longitudinal Data presented by Replica Analytics
In this webinar, Replica Analytics’ Dr. Khaled El Emam is joined by Director of Data Science Lucy Mosquera to provide a general introduction to synthetic data generation (SDG), explaining what it means, how it works and what technologies are used, as well as an overview of the use cases where synthetic data can provide value in the context of real-world data and clinical trial data in collaboration with C-Path. Given the paucity of data that exists for rare disease drug development, synthetic data may augment the limited data that does exist to support patient selection, patient phenotype characterization and clinical trial design. This presentation will also address the value of synthetic data in the context of rare disease drug development.
Replica Analytics, a pioneer in using artificial intelligence (AI) for synthetic health data generation, is part of Aetion, the leading regulatory-grade real-world evidence (RWE) technology provider. Its AI technology generates synthetic, privacy-protected copies of real-world data (RWD) that preserve the integrity and utility of source data.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling $13,239,950, and 45.8% funded by non-government source(s), totaling $11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.